Enanta Pharmaceuticals Reports Positive Topline Results from Phase 2 SPRINT Trial Evaluating EDP-235 in Standard Risk Patients with COVID-19
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
| ENANTA PHARM (NASDAQ: ENTA) | Delayed: 11.31 -0.36 (3.08%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $11.67 | 52 Week High | $34.49 | |||
| Open | $11.64 | 52 Week Low | $20.39 | |||
| Day High | $11.85 | P/E | N/A | |||
| Day Low | $11.24 | EPS | $-3.18 | |||
| Volume | 166,830 | |||||
